AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, ...
Not a lot of stocks can be bought for less than $20, and many sub-$20 stocks are best avoided by most investors. However, ...